drugset / Trial / NCT03227432
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a combination of targeted therapies as a possible treatment for multiple myeloma (MM). The drugs involved in this study are: * Elotuzumab * Nivolumab * Pomalidomide * Dexamethasone
Timeline
- Start
- 2018-12
- Primary completion
- 2021-12-31
- Completion
- 2024-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Elotuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pomalidomide | Other / unclassified | — | — |